Clinical Trial Detail

NCT ID NCT02392507
Title A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company

lung non-small cell carcinoma


Carboplatin + Nab-paclitaxel + Necitumumab

Age Groups: adult

No variant requirements are available.